Medical device cybersecurity is different from general product security because the stakes include patient safety, clinical continuity, and regulatory readiness. Connected devices now sit inside hospital networks, home-care environments, and cloud-connected care ecosystems, which means manufacturers have to think about cybersecurity across design, submission, release, monitoring, and update planning. The FDA’s cybersecurity framework is centered on premarket submission expectations and postmarket vulnerability management, and it now intersects directly with statutory requirements for many “cyber devices” under section 524B of the FD&C Act.
Vultara helps medical device manufacturers manage that work with structured cybersecurity workflows, traceability, and lifecycle visibility in an on-premises deployment model built for organizations that want tighter control over sensitive engineering, quality, and product-security data.


Medical device teams have to balance security with safety, usability, regulatory documentation, and real-world care delivery. Devices may be difficult to patch quickly, may remain deployed for years, and may operate in environments where downtime is not trivial. That is why the FDA continues to frame cybersecurity as a lifecycle responsibility, not a one-time submission task.
The FDA’s current premarket guidance, Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions, recommends security-focused design and labeling practices and calls for documentation such as threat modeling as part of premarket submissions for devices with cybersecurity risk. FDA also states that manufacturers of covered cyber devices must submit the section 524B information in applicable premarket submissions.
On the postmarket side, the FDA’s guidance on Postmarket Management of Cybersecurity in Medical Devices emphasizes ongoing vulnerability management for marketed and distributed devices and explicitly encourages manufacturers to address cybersecurity throughout design, development, production, distribution, deployment, and maintenance.
A key standards reference in this space is IEC 81001-5-1, which defines secure health software lifecycle requirements and provides a common framework for secure health software lifecycle processes.
Medical device manufacturers usually do not struggle because they lack awareness of FDA cybersecurity expectations. They struggle because evidence, risk decisions, and engineering work get scattered across quality, regulatory, software, systems, and security teams. Threat models go stale. Submission artifacts become painful to maintain. Postmarket follow-through becomes harder once devices are released into real clinical environments.
Vultara helps medical device teams turn cybersecurity into a repeatable process instead of a documentation scramble. Teams can standardize risk-management workflows, maintain traceability between risks and mitigations, support premarket documentation readiness, and keep better visibility into postmarket responsibilities as products evolve.
For medical devices, that means a more practical way to manage cybersecurity across FDA premarket expectations, postmarket vulnerability management, and secure product lifecycle activities without pushing sensitive data into a cloud-first tool.
As connected care expands, medical device cybersecurity expectations will keep rising. FDA guidance, section 524B obligations for cyber devices, and secure lifecycle standards like IEC 81001-5-1 all point in the same direction: manufacturers need more structured and more defensible cybersecurity practices.
Vultara helps medical device organizations respond with structure, visibility, and control.
Talk to Vultara about improving medical device cybersecurity workflows.
Copyright © 2026 Vultara, Inc. - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.